CRISPR Therapeutics (NASDAQ:CRSP) Price Target Raised to $120.00

CRISPR Therapeutics (NASDAQ:CRSP) had its price objective boosted by Truist Financial from $100.00 to $120.00 in a research note issued to investors on Wednesday,Benzinga reports. Truist Financial currently has a buy rating on the stock.

Other equities research analysts have also recently issued reports about the company. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a report on Monday, December 30th. HC Wainwright assumed coverage on CRISPR Therapeutics in a report on Monday, February 3rd. They set a “buy” rating and a $65.00 price target for the company. Bank of America dropped their price target on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Chardan Capital reissued a “buy” rating and issued a $94.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday, December 10th. Finally, Royal Bank of Canada lowered their target price on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a research note on Wednesday. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $74.50.

CRISPR Therapeutics Price Performance

CRISPR Therapeutics stock opened at $49.72 on Wednesday. The company has a market capitalization of $4.26 billion, a PE ratio of -17.57 and a beta of 1.67. CRISPR Therapeutics has a one year low of $36.52 and a one year high of $91.10. The business has a 50 day simple moving average of $41.89 and a 200 day simple moving average of $46.17.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. Equities analysts anticipate that CRISPR Therapeutics will post -5.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of CRISPR Therapeutics stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the transaction, the chief executive officer now directly owns 181,540 shares in the company, valued at approximately $10,002,854. The trade was a 7.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 4.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CRSP. Highline Wealth Partners LLC bought a new position in CRISPR Therapeutics during the fourth quarter worth about $39,000. Western Pacific Wealth Management LP lifted its holdings in CRISPR Therapeutics by 100.0% during the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock worth $39,000 after acquiring an additional 500 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new position in CRISPR Therapeutics during the third quarter worth about $40,000. Darwin Wealth Management LLC bought a new position in CRISPR Therapeutics during the third quarter worth about $43,000. Finally, Eastern Bank bought a new position in CRISPR Therapeutics during the third quarter worth about $70,000. 69.20% of the stock is currently owned by institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.